BEDOGNI, G., BELLENTANI, S., MIGLIOLI, L., MASUTTI, F., PASSALACQUA, M., CASTIGLIONE, A. & TIRIBELLI, C. 2006. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC gastroenterology, 6, 1-7.
BERENBAUM, F. 2013. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis and cartilage, 21, 16-21.
BERENBAUM, F., EYMARD, F. & HOUARD, X. 2013. Osteoarthritis, inflammation and obesity. Current opinion in rheumatology, 25, 114-118.
BYRNE, C. D. & TARGHER, G. 2015. NAFLD: a multisystem disease. Journal of hepatology, 62, S47-S64.
CHALASANI, N., YOUNOSSI, Z., LAVINE, J. E., DIEHL, A. M., BRUNT, E. M., CUSI, K., CHARLTON, M. & SANYAL, A. J. 2012. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology, 55, 2005-2023.
CHO, H., KIM, Y.-L., JEONG, Y.-J. & JUNG, J. 2018. Associations between Osteoarthritis and Metabolic Syndrome in Korean Adult: The 5th Korean National Health and Nutrition Examination Survey, 2010-2012. Korean Journal of Family Practice, 8, 292-298.
CRAIG, C. L., MARSHALL, A. L., SJøSTRøM, M., BAUMAN, A. E., BOOTH, M. L., AINSWORTH, B. E., PRATT, M., EKELUND, U., YNGVE, A. & SALLIS, J. F. 2003. International physical activity questionnaire: 12-country reliability and validity. Medicine & science in sports & exercise, 35, 1381-1395.
ENGSTRøM, G., DE VERDIER, M. G., ROLLOF, J., NILSSON, P. & LOHMANDER, L. 2009. C-reactive protein, metabolic syndrome and incidence of severe hip and knee osteoarthritis. A population-based cohort study. Osteoarthritis and Cartilage, 17, 168-173.
ESLAM, M., NEWSOME, P. N., ANSTEE, Q. M., TARGHER, G., GOMEZ, M. R., ZELBER-SAGI, S., WONG, V. W.-S., DUFOUR, J.-F., SCHATTENBERG, J. & ARRESE, M. 2020a. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. Journal of hepatology.
ESLAM, M., SANYAL, A. J., GEORGE, J., SANYAL, A., NEUSCHWANDER-TETRI, B., TIRIBELLI, C., KLEINER, D. E., BRUNT, E., BUGIANESI, E. & YKI-JæRVINEN, H. 2020b. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 158, 1999-2014. e1.
ESLAM, M., SARIN, S. K., WONG, V. W.-S., FAN, J.-G., KAWAGUCHI, T., AHN, S. H., ZHENG, M.-H., SHIHA, G., YILMAZ, Y. & GANI, R. 2020c. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatology international, 1-31.
FEDCHUK, L., NASCIMBENI, F., PAIS, R., CHARLOTTE, F., HOUSSET, C., RATZIU, V. & GROUP, L. S. 2014. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Alimentary pharmacology & therapeutics, 40, 1209-1222.
FOUAD, Y., WAKED, I., BOLLIPO, S., GOMAA, A., AJLOUNI, Y. & ATTIA, D. 2020. What's in a name? Renaming ‘NAFLD’to ‘MAFLD’. Liver international, 40, 1254-1261.
FRIEDMAN, S. L., NEUSCHWANDER-TETRI, B. A., RINELLA, M. & SANYAL, A. J. 2018. Mechanisms of NAFLD development and therapeutic strategies. Nature medicine, 24, 908-922.
GASTALDELLI, A., KOZAKOVA, M., HúJLUND, K., FLYVBJERG, A., FAVUZZI, A., MITRAKOU, A., BALKAU, B. & INVESTIGATORS, R. 2009. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology, 49, 1537-1544.
GRIFFIN, T. M. & GUILAK, F. 2008. Why is obesity associated with osteoarthritis? Insights from mouse models of obesity. Biorheology, 45, 387-398.
HUANG, X., XU, M., CHEN, Y., PENG, K., HUANG, Y., WANG, P., DING, L., LIN, L., XU, Y. & CHEN, Y. 2015. Validation of the fatty liver index for nonalcoholic fatty liver disease in middle-aged and elderly Chinese. Medicine, 94.
KELLGREN, J. & LAWRENCE, J. 1957. Radiological assessment of osteo-arthrosis. Annals of the rheumatic diseases, 16, 494.
KHANG, A. R., LEE, H. W., YI, D., KANG, Y. H. & SON, S. M. 2019. The fatty liver index, a simple and useful predictor of metabolic syndrome: analysis of the Korea National Health and Nutrition Examination Survey 2010–2011. Diabetes, metabolic syndrome and obesity: targets and therapy, 12, 181.
KIM, D., CHOI, S. Y., PARK, E. H., LEE, W., KANG, J. H., KIM, W., KIM, Y. J., YOON, J. H., JEONG, S. H. & LEE, D. H. 2012. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology, 56, 605-613.
KIM, M. K., AHN, C. W., NAM, J. S., KANG, S., PARK, J. S. & KIM, K. R. 2015. Association between nonalcoholic fatty liver disease and coronary artery calcification in postmenopausal women. Menopause (New York, NY), 22, 1323.
KOEHLER, E. M., SCHOUTEN, J. N., HANSEN, B. E., HOFMAN, A., STRICKER, B. H. & JANSSEN, H. L. 2013. External validation of the fatty liver index for identifying nonalcoholic fatty liver disease in a population-based study. Clinical Gastroenterology and Hepatology, 11, 1201-1204.
LOOMBA, R. & SANYAL, A. J. 2013. The global NAFLD epidemic. Nature reviews Gastroenterology & hepatology, 10, 686-690.
MASUKO, K., MURATA, M., SUEMATSU, N., OKAMOTO, K., YUDOH, K., NAKAMURA, H. & KATO, T. 2009. A metabolic aspect of osteoarthritis: lipid as a possible contributor to the pathogenesis of cartilage degradation. Clinical & Experimental Rheumatology, 27, 347.
MOTAMED, N., SOHRABI, M., AJDARKOSH, H., HEMMASI, G., MAADI, M., SAYEEDIAN, F. S., PIRZAD, R., ABEDI, K., AGHAPOUR, S. & FALLAHNEZHAD, M. 2016. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World journal of gastroenterology, 22, 3023.
NIU, J., CLANCY, M., ALIABADI, P., VASAN, R. & FELSON, D. T. 2017. Metabolic syndrome, its components, and knee osteoarthritis: the Framingham Osteoarthritis Study. Arthritis & Rheumatology, 69, 1194-1203.
SELLAM 2013. Osteoarthritis as a disease of mechanics. Osteoarthritis and cartilage, 21, 10-15.
SVIKLĀNE, L., OLMANE, E., DZĒRVE, Z., KUPČS, K., PĪRĀGS, V. & SOKOLOVSKA, J. 2018. Fatty liver index and hepatic steatosis index for prediction of non‐alcoholic fatty liver disease in type 1 diabetes. Journal of gastroenterology and hepatology, 33, 270-276.
THIJSSEN, E., VAN CAAM, A. & VAN DER KRAAN, P. M. 2015. Obesity and osteoarthritis, more than just wear and tear: pivotal roles for inflamed adipose tissue and dyslipidaemia in obesity-induced osteoarthritis. Rheumatology, 54, 588-600.
VALENTI, L. & PELUSI, S. 2020. Redefining fatty liver disease classification in 2020.
YOSHIMURA, N., MURAKI, S., OKA, H., KAWAGUCHI, H., NAKAMURA, K. & AKUNE, T. 2011. Association of knee osteoarthritis with the accumulation of metabolic risk factors such as overweight, hypertension, dyslipidemia, and impaired glucose tolerance in Japanese men and women: the ROAD study. The Journal of rheumatology, 38, 921-930.
ZELBER-SAGI, S., WEBB, M., ASSY, N., BLENDIS, L., YESHUA, H., LESHNO, M., RATZIU, V., HALPERN, Z., OREN, R. & SANTO, E. 2013. Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World journal of gastroenterology: WJG, 19, 57.
ZHUO, Q., YANG, W., CHEN, J. & WANG, Y. 2012. Metabolic syndrome meets osteoarthritis. Nature Reviews Rheumatology, 8, 729.